Free Trial
NASDAQ:SLNO

Soleno Therapeutics (SLNO) Stock Price, News & Analysis

$41.16
-0.01 (-0.02%)
(As of 05/24/2024 ET)
Today's Range
$40.68
$42.43
50-Day Range
$37.14
$49.23
52-Week Range
$3.69
$53.82
Volume
302,603 shs
Average Volume
612,047 shs
Market Capitalization
$1.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.33

Soleno Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.14 Rating Score
Upside/​Downside
46.6% Upside
$60.33 Price Target
Short Interest
Bearish
16.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.47mentions of Soleno Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$36.94 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.36) to ($2.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.79 out of 5 stars

Medical Sector

259th out of 917 stocks

Electromedical Equipment Industry

4th out of 18 stocks

SLNO stock logo

About Soleno Therapeutics Stock (NASDAQ:SLNO)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

SLNO Stock Price History

SLNO Stock News Headlines

Soleno Therapeutics (SLNO) Receives a Buy from Stifel Nicolaus
SLNO Apr 2024 40.000 put
See More Headlines
Receive SLNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
5/25/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:SLNO
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$60.33
High Stock Price Target
$93.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+46.6%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-38,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.29 per share

Miscellaneous

Free Float
29,301,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
-1.51
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Anish Bhatnagar M.D. (Age 54)
    President, CEO, COO & Director
    Comp: $1.06M
  • Mr. James H. MacKanessMr. James H. MacKaness (Age 60)
    Chief Financial Officer
    Comp: $640k
  • Ms. Patricia C. Hirano M.P.H. (Age 58)
    Senior Vice President of Regulatory Affairs
    Comp: $493k
  • Ms. Lauren Budesheim
    Vice President of People
  • Ms. Kristen Yen M.S. (Age 55)
    Senior Vice President of Clinical Operations
    Comp: $317.19k
  • Dr. Neil M. Cowen M.B.A.
    Ph.D., Senior Vice President of Drug Development
  • Ms. Meredith Manning M.B.A. (Age 52)
    Chief Commercial Officer
  • Dr. Michael Huang M.D. (Age 50)
    Senior Vice President of Clinical Development

SLNO Stock Analysis - Frequently Asked Questions

Should I buy or sell Soleno Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLNO shares.
View SLNO analyst ratings
or view top-rated stocks.

What is Soleno Therapeutics' stock price target for 2024?

7 Wall Street analysts have issued twelve-month target prices for Soleno Therapeutics' shares. Their SLNO share price targets range from $35.00 to $93.00. On average, they expect the company's share price to reach $60.33 in the next year. This suggests a possible upside of 46.6% from the stock's current price.
View analysts price targets for SLNO
or view top-rated stocks among Wall Street analysts.

How have SLNO shares performed in 2024?

Soleno Therapeutics' stock was trading at $40.25 on January 1st, 2024. Since then, SLNO shares have increased by 2.3% and is now trading at $41.16.
View the best growth stocks for 2024 here
.

When is Soleno Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our SLNO earnings forecast
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.02.

What ETFs hold Soleno Therapeutics' stock?
When did Soleno Therapeutics' stock split?

Shares of Soleno Therapeutics reverse split on the morning of Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Carlyle Group Inc. (12.19%), Janus Henderson Group PLC (8.59%), Avoro Capital Advisors LLC (4.86%), Price T Rowe Associates Inc. MD (0.46%), StemPoint Capital LP (0.35%) and Allspring Global Investments Holdings LLC (0.31%). Insiders that own company stock include Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen, Perceptive Advisors Llc and Vivo Opportunity, Llc.
View institutional ownership trends
.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLNO) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners